A series of novel benzyloxyurea derivatives was designed, synthesized by substituting different benzyls or phenyls on N,N′-positions of the hydroxyurea (HU). These target compounds were evaluated for their anticancer activity in vitro against human leukemia cell line K562 and murine leukemia cell line L1210 in comparison with HU by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Some of the compounds showed promising anticancer activity against the cells. Molecular docking experiments with Saccharomyces cerevisiae R1 domain indicated that 4a and 4f′ have stronger affinity than 4m and 4n. Flow cytometry study showed that compound 4g exerted greater apoptotic activity against K562 cells line than HU.
Synthesis and Anticancer Evaluation of Benzyloxyurea Derivatives
As we all know, because of its low cure rate and high mortality, tumor has become one of the most terrible diseases around the world. Hydroxyurea (HU), as the preferred treatment drug of chronic myelogenous leukemia, could also be used to treat melanoma, tumor of the ovary, human immunodeficiency virus (HIV) infection, β-mediterranean disease and so on. [1] [2] [3] [4] [5] But the use of HU is limited by its metabolic and inherent cytotoxicity. [6] [7] [8] [9] Eukaryotic ribonucleoside reductase (RR) catalyzes nucleoside diphosphate conversion to deoxynucleoside diphosphate. Crucial for rapidly dividing cells, RR is an attractive therapeutic target of cancer, and over the past years, many chemotherapeutics inhibiting different subunits of RR have been developed and tested clinically for their anticancer activities and anti-HIV activities. [10] [11] [12] [13] HU is the first RR inhibitor applied to the clinic, and is utilized for the therapeutic of neoplasms because of its influences on the DNA replication of cancer cells. 1, 14) To overcome the drawbacks of HU, numerous medicinal chemistry efforts have been made to design and synthesize novel HU derivatives. 9, [15] [16] [17] [18] In previous paper, we reported HU monosubstituents and disubstituents with benzyls at N-positions of HU. 6, 19) The results indicated that the stronger hydrophobic nature of the HU derivatives might favor the cytotoxic activity and benzyl groups at the N-position of HU were associated with enhanced cytotoxic activity. The disadvantages associated with HU's physicochemical properties, e.g., very high hydrophilicity (log P: −1.80) and small molecular size, may be overcomed by the structural modification. This background prompted us to further explore more novel benzyloxyurea derivatives with different substituents at N,N′-positions of HU. In this study, a series of novel benzyloxyurea derivatives substituted with different benzyls or phenyls at N,N′-position of HU were synthesized. The target compounds were evaluated for their anticancer activity in vitro against human leukemia cell line K562 and murine leukemia cell line L1210 in comparison with HU by the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay. Meanwhile, the technology of molecular docking and flow cytometry were used to some of the high active compounds, which revealed many useful information.
Results and Discussion
Chemistry The carbamate intermediates 3a-g were synthesized via three steps. In the presence of CH 3 CH 2 ONa, acetoxime and various substituted benzyl chloride were added in anhydrous CH 3 CH 2 OH at room temperature to give 1a-g, which were then treated with concentrated HCl to afford 2a-g. In the presence of pyridine, compounds 2a-g were treated with 4-nitrophenyl chloroformate in CH 2 Cl 2 to give 3a-g, [19] [20] [21] [22] which were converted to target compounds 4a-u in the presence of Et 3 N in CH 2 Cl 2 with substituted anilines or p-phenylenediamine at room temperature (Chart 1). Target compounds 4a′-g′ 23) could be provided in the presence of Na 2 CO 3 with hydroxylamine hydrochloride in CH 3 OH and CH 2 Cl 2 .
Anticancer Activity The prepared compounds 4a-u and 4a′-g′ were evaluated for cytotoxic properties on human leukemia cell line K562 and murine leukemia cell line L1210 with HU as positive control. Inhibition of cell-proliferation was measured by the improved MTT assay. 6, 24) The inhibitory potency (IC 50 ) of tested compounds are given in Table 1 . In general, some target compounds showed good inhibitory effects on L1210 and K562, especially 4a, 4b, 4d, 4e, 4g, 4q, 4c′ and 4f′. Among these compounds, 4a-g, 4j, 4k, 4p, 4q, 4t, 4c′ and 4f′ exhibited stronger inhibitory effects on L1210 than HU, wherein the anticancer activity of 4g (IC 50 : 15.31 µM) and 4b (IC 50 : 22.61 µM) were the highest two compounds. 4a, 4b, 4d, 4e, 4g, 4l, 4o, 4q, 4s and 4a′-g′ showed higher activity on K562 than HU, wherein 4f′ (IC 50 : 1.32 µM), 4g′ (IC 50 : 3.84 µM) revealed the highest inhibitory effect on K562. Nevertheless, the inhibitory activities of 4h, 4i, 4m, 4n, 4r and 4u were lower than HU no matter on K562 or L1210.
Apoptosis Assay for Compound 4g by Flow Cytometry Among the twenty-eight compounds tested for anti-proliferative effect, nine compounds 4a, 4b, 4d, 4e, 4f, 4g, 4q, 4c′, 4f′ showed a significant inhibition of proliferation for the two cancer cell lines, among these 4g exhibited the best activity to L1210 cells and the nearly equipotent activity to K562 cells with HU. In order to investigate whether the potent compounds exhibited their anti-proliferative effect on K562 cancer cell through induction of apoptosis, the compound 4g was se-lected for further apoptosis assay in comparison with HU. The studies of flow cytometry were undertaken on compound 4g and HU in five different concentrations. The results shown in Fig. 1 and Table 2 revealed that compound 4g exhibited higher population of apoptotic cells than HU at the same concentration. The results indicated 4g could induce apoptosis of K562 cancer cells.
Molecular Docking Study In order to determine the interactions between target compounds and RR. The potent compounds 4a and 4f′, as well as the least active compounds 4m and 4n were docked into the active site of RR by autodock tool 1.5.2 version. RR activity requires formation of a complex between subunits R1 and R2 in which the R2 C-terminal peptide binds to R1. The subsite A and subsite B in Saccharomyces cerevisiae R1 (ScR1) domain of RR are the active site in which R2 C-terminal heptapeptide, P7 and its peptidomimetic P6 bound to ScR1. P7 and P6, both of which inhibit ScRR. 25) So the subsite B (PDB id-2ZLF) was selected as the receptor. The interior of the cavity in subsite B was narrow and consisted of two pockets accommodating the hydrophobic residues. These residues were on the pocket A LEU716, ARG717, GLN692, and on the pocket B LYS723, SER726, MET727, LYS693, ILE696 and TYR730.
The compounds 4a and 4f′, which displayed the high anticancer activity, were embedded into the cleft of two pockets in the active site (Fig. 2) . Good complementarities were observed between the docked ligand and the hydrophobic subsites of the enzymatic cavity. In the pocket A, the benzyl group of 4a and the hydroxylamine group of 4f′ were stabilized by LEU716, ARG717 and GLN692, while the phenyl group of 4a and the benzyl group of 4f′ interacted with the residues LYS723, MET727, LYS693 and TYR730 of the pocket B. The hydrogen bonds were identified between GLN 692 and LEU716 and the acyl group of the ligand (Fig. 3) . The docking conformation of compounds 4m and 4n, superposed to the one of compounds 4a and 4f′ in Fig. 2 , showed the different docking poses and hydrogen bond interactions. Because of the bulky substituent structures, 4m and 4n could not be embed the pocket A, and they formed hydrogen bonds by the acyl group with residue LYS693 on the pocket B. The compound 4m interacted with the residues LYS723, SER726, MET727, LYS693, ILE696, TYR730 of the pocket B and GLN 692 of the pocket A (Fig.  4) . Because compound 4m could not interacte with residues LEU716 and ARG717 in the interior of the pocket A, the binding of 4m to the active site was decreased. This molecular modeling study into the active site of RR allowed to provide a rationale to the increasing activity measured for 4a and 4f′ compared to 4m and 4n. Building up a p-phenylene bis benzyloxyurea structures had a negative effect on the activity. This suggested that the smaller substituent groups were preferred on the nitrogen atom of HU, giving a moderate increase of binding affinity. 
Conclusion
The anticancer activity of the newly synthesized benzyloxyurea derivatives 4a-u and 4a′-g′ was estimated by studying their inhibitory effects on human leukemia cell line K562 and murine leukemia cell line L1210. Some compounds showed improved anticancer activity on L1210 and K562 cell lines compared to HU. Among them, the most promising compounds were 4a, 4b, 4d, 4e, 4g, 4q, 4c′ and 4f′, showed stronger effect than that of HU in both L1210 and K562 cell lines. Among the 1,4-phenylene bis benzyloxyurea derivatives 4h-n, 4h, 4i, 4m and 4n were inactive no matter on K562 or L1210 cell line, indicating the bulky substituents on the HU nitrogen had a negative effect on the activity. Then, a molecular docking study of the four compounds revealed potential binding mode into the RR receptor, and explained the main structureactivity relationships. Moreover, flow cytometry analysis of compound 4g showed that it could induce apoptosis of K562 significantly than HU.
Experimental
Materials Substituted benzyl chloride and acetoxime, as well as substituted anilines and 4-nitrophenyl chloroformate were purchased from Shanghai Da Rei Finechemical Co., Ltd., other commercial solvents were purchased from Sinopharm Group Co., Ltd. All reagents were used without further purification unless stated.
Apparatus Infrared spectra were measured on KBr pellets on a Shimadzu FTIR-8400 spectrometer in the range of 4000-400 cm C-NMR spectra were performed on Brucker AV 600 spectrometer. Chemical shifts (δ values) and coupling constants (J values) were reported in parts per million (ppm) and hertz (Hz), respectively. Chemical shifts were relative to tetramethylsilane (TMS) except for solvents that were used, and the signals were quoted as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). The mass spectra (electrospray ionization (ESI)) were recorded on Agilent 1100 MSD/TOF and Waters 2695 LC-ZQ4000. Melting points were obtained on a XA-4 instrument which was uncorrected.
Synthesis of Compounds 2a-g General Procedure
Intermediates 1a-g were prepared following our previous paper. 19) The obtained yellow oily liquid 1a-g were added dropwise to concentrated hydrochloric acid. The mixture was stirred at room temperature for 5 h and was distilled under reduced The compounds are color coded as carbon nattier blue (4a), beige (4f′), nitrogen blue, oxygen red and hydrogen purple. The hydrogen bonds are drawn in nattier blue lines. The compound is color coded as carbon black, nitrogen blue, oxygen red and hydrogen white. The hydrogen bonds are drawn in nattier blue lines. The compounds are color coded as carbon green (4m), pink (4a), nattier blue (4f′) and beige (4n), nitrogen blue, oxygen red and hydrogen white. The hydrogen bonds are drawn in red lines. Protein is represented by the molecular surface. N,N′-(1,4-Phenylene)-bis-[N″-(3′-chlorobenzyloxy) Synthesis of Compounds 4o-u General Procedure To a stirring solution of 4-NH 2 substituted aniline (3.0 mmol) and anhydrous Et 3 N (7.2 mmol) in CH 2 Cl 2 (25 mL), compounds 3a-g (3.0 mmol) were added and stirred for 18 h at room temperature. The resulting mixture was filtered and the filtrate was adjusted to pH= 1 with 1 mol/L HCl, diluted with CH 2 Cl 2 (30 mL) and extracted with H 2 O (40 mL×3). The water phases were combined and adjusted to pH >7 with Na 2 CO 3 . Subsequently, the solution was extracted with CH 2 Cl 2 (40 mL×3), the combined extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford oil liquid, which was recrystallized from CH 2 Cl 2 and petroleum ether to give target compounds 4o-u. Synthesis of Compounds 4a′-g′ General Procedure A suspension of hydroxylamine hydrochloride (0.02 mol) and Na 2 CO 3 (0.02 mol) in anhydrous CH 3 OH (70 mL) was stirred at room temperature for 0.5 h. Compounds 3a-g were dissolved in anhydrous CH 2 Cl 2 (140 mL) previously, and were added to the corresponding mixture and stirred for another 4 h. The reaction mixture was filtered, and the filtrate was evaporated, the residue was subjected to column chromatography (EtOAc/ petroleum ether: 1/2) to give target compounds 4a′-g′. 
N-(4-Aminophenyl)-N′-benzyloxyurea

Cytotoxicity Assay in Vitro
The murine leukemia cell line L1210 and human K562 leukemia cell line were purchased from Nanjing Keygen Biotech. Co., Ltd., China. The cell lines were cultured in improved RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 IU/mL penicillin G and 100 IU/mL streptomycin sulfate in a humidified, 5% CO 2 atmosphere at 37°C. According to the growth situation cell lines, the culture solution was centrifuged every two to three days with low-speed. The logarithmic growth phase cells were collected for experiments. The cytotoxicities of the target compounds against L1210 and K562 cell lines were examined by the MTT assay. Tumor cells (1×10 6 cells/mL) were inoculated in 96-well culture plates (90 µL/well). Then 10 µL of culture medium containing synthetic compound of various concentrations was added to the wells, then the cells were incubated for 48 h at 37°C in 5% CO 2 atmosphere. Twenty microliters of MTT was added at a final concentration of 5 mg/mL and after 4 h incubation, 100 µL Triple solution (10% SDS, 5% isobutanol, 0.01 mol/L HCl) were added. The suspension was placed in the dark incubator at 37°C overnight and the optical density was measured at 570 nm.
Apoptosis Assay Flow cytometry was undertaken on the instrument of FACS Calibur (Beckman Coulter Co., U.S.A.) with Annexin V-fluorescein isothiocyanate (FITC)/ PI, Nanjing Keygen Technology Development Co., China) as detection kits, and hydroxyurea as positive control drug. The logarithmic growth phase of K562 cell line was washed with Phosphate Buffered Saline (PBS, Nanjing Keygen Technology Development Co., China) and centrifuged for 5 min. The cells were seeded at a density of 5×10 5 cells/well. After 24 h at 37°C in 5%CO 2 atmosphere, l-5×10 5 K562 cells were collected and suspended with Binding Buffer (500 µL), then Annexin V-FITC (5 µL) and PI (5 µL) were added and incubated 10 min at room temperature. After that, the fluorescence of K562 cells were measured no more than 1 h using a flow cytometer.
